Editorial: infliximab or adalimumab as first‐ or second‐line anti‐TNF—conflicting evidence—authors' reply. Issue 6 (23rd August 2021)

• Record Type: Journal Article
• Authors: Visuri, Isabella; Eriksson, Carl; Olén, Ola; Cao, Yang; Mårdberg, Emelie; Grip, Olof; Gustavsson, Anders; Hjortswang, Henrik; Karling, Pontus; Montgomery, Scott; Myrelid, Pär; Ludvigsson, Jonas F.; Halfvarson, Jonas
• Is Part Of: Alimentary pharmacology & therapeutics. Volume 54:Issue 6(2021)
• Page Start: 848
• Page End: 849
• Publication Date: 2021-08-23
• Subjects: Digestive organs -- Diseases -- Treatment -- Periodicals; Digestive organs -- Effect of drugs on -- Periodicals; Gastrointestinal system -- Diseases -- Treatment -- Periodicals; Gastrointestinal system -- Effect of drugs on -- Periodicals; 615.73
• DOI: 10.1111/apt.16569
• Languages: English
• ISSNs: 0269-2813

Abstract

LINKED CONTENT: This article is linked to Visuri et al and Haydek & Scott papers. To view these articles, visit https://doi.org/10.1111/apt.16525 and https://doi.org/10.1111/apt.16555